Early peripheral responses to intravenous L-thyroxine in primary hypothyroidism.
The metabolic, cardiovascular, renal, and pulmonary responses of 10 hypothyroid patients were studied during the first week of therapy with intravenous levothyroxine (L-thyroxine), 100 micrograms per day. Mean serum thyroxine, triiodothyronine, and reverse triiodothyronine concentrations were normalized within four days. Significant decreases in serum thyrotropin, creatine phosphokinase, and cholesterol levels, and an increase in the basal metabolic rate, were observed. An early cardiovascular response was demonstrated by serial measurement of the mean pre-ejection period (138 to 134 msec, p less than 0.05), its ratio to left ventricular ejection time (0.49 to 0.46, p less than 0.02), and pulse-wave arrival time (236 to 224 msec, p less than 0.05). The mean renal excretion of a water load (four hours) increased (54 to 77 percent, p less than 0.02) by the fourth day. The blunted ventilatory responses to hypercapnea seen in two patients were improved. We conclude that a physiologic replacement dose of intravenous L-thyroxine for one week produces significant responses in organ systems responsible for the common clinical complications of myxedema.
D000328:Adult; D000368:Aged; D001481:Basal Metabolism; D001834:Body Water / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy* / Q000378:metabolism; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009230:Myxedema / Q000150:complications; D010901:Pituitary Function Tests; D013318:Stroke Volume / Q000187:drug effects; D013960:Thyroid Function Tests; D013970:Thyronines / Q000097:blood; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage* / Q000627:therapeutic use
D013970:Thyronines; D013972:Thyrotropin; D002784:Cholesterol; D003402:Creatine Kinase; D013974:Thyroxine